Jazz Pharmaceuticals (JAZZ) financial statements
Jazz Pharmaceuticals reported revenue of $4.3B in fiscal 2025, up 12.4% a year over 9 years.
Net income was -$356M and the operating margin -10.1%, against 39.8% in 2016.
Free cash flow was $1.3B, and the company returned $125M in net buybacks.
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Jazz Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B | $1.6B | $1.9B | $2.2B | $2.4B | $3.1B | $3.7B | $3.8B | $4.1B | $4.3B |
| Research and development | $162M | $198M | $227M | $300M | $335M | $506M | $590M | $850M | $884M | $783M |
| Selling, general and admin | $503M | $544M | $684M | $737M | $854M | $1.5B | $1.4B | $1.3B | $1.4B | $1.8B |
| Operating income | $592M | $529M | $615M | $532M | $378M | $170M | -$66M | $579M | $717M | -$430M |
| Interest expense | $28M | $38M | $57M | $62M | $88M | $90M | $33M | $33M | — | — |
| Pre-tax income | $532M | $441M | $529M | $454M | $275M | -$113M | -$373M | $298M | $470M | -$628M |
| Income tax | $135M | -$48M | $80M | -$73M | $34M | $216M | -$159M | -$120M | -$91M | -$272M |
| Net income | $397M | $488M | $447M | $523M | $239M | -$330M | -$224M | $415M | $560M | -$356M |
| EPS (diluted) | $6.41 | $7.96 | $7.30 | $9.09 | $4.22 | -$5.52 | -$3.58 | $6.10 | $8.65 | -$5.84 |
| Diluted shares | 62M | 61M | 61M | 58M | 57M | 60M | 63M | 72M | 66M | 61M |
| Operating margin | 39.8% | 32.7% | 32.5% | 24.6% | 16.0% | 5.5% | -1.8% | 15.1% | 17.6% | -10.1% |
| Net margin | 26.7% | 30.1% | 23.6% | 24.2% | 10.1% | -10.7% | -6.1% | 10.8% | 13.8% | -8.3% |
Balance sheet
Fiscal years, from Jazz Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $366M | $386M | $310M | $637M | $1.1B | $591M | $881M | $1.5B | $2.4B | $2.4B |
| Receivables | $234M | $224M | $264M | $356M | $396M | $563M | $651M | $706M | $717M | $831M |
| Inventory | $34M | $43M | $53M | $79M | $95M | $1.1B | $714M | $597M | $480M | $417M |
| Total current assets | $748M | $968M | $1.2B | $1.6B | $2.8B | $2.6B | $2.6B | $3.4B | $4.6B | $4.2B |
| Property, plant and equipment | $107M | $170M | $200M | $132M | $128M | $257M | $228M | $170M | $173M | $200M |
| Goodwill | $894M | $948M | $928M | $920M | $958M | $1.8B | $1.7B | $1.8B | $1.7B | $1.8B |
| Total assets | $4.8B | $5.1B | $5.2B | $5.5B | $6.5B | $12.3B | $10.8B | $11.4B | $12.0B | $11.7B |
| Total current liabilities | $257M | $294M | $345M | $364M | $654M | $809M | $933M | $1.5B | $1.0B | $2.2B |
| Long-term debt | $2.0B | $1.5B | $1.6B | $1.6B | $1.8B | $6.0B | $5.7B | $5.1B | $6.1B | $4.3B |
| Total liabilities | $2.9B | $2.4B | $2.4B | $2.4B | $2.9B | $8.3B | $7.7B | $7.7B | $7.9B | $7.3B |
| Shareholders' equity | $1.9B | $2.7B | $2.8B | $3.1B | $3.7B | $4.0B | $3.1B | $3.7B | $4.1B | $4.3B |
| Net debt | $1.7B | $1.2B | $1.3B | $970M | $1.0B | $5.5B | $4.8B | $4.2B | $3.7B | $4.0B |
Cash flow
Fiscal years, from Jazz Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $592M | $693M | $799M | $776M | $900M | $779M | $1.3B | $1.1B | $1.4B | $1.4B |
| Capital spending | $10M | $29M | $20M | $40M | $15M | $28M | $29M | $24M | $38M | $59M |
| Free cash flow | $583M | $664M | $779M | $736M | $885M | $751M | $1.2B | $1.1B | $1.4B | $1.3B |
| Stock-based compensation | $99M | $107M | $102M | $111M | $121M | $189M | $222M | $227M | $248M | $291M |
| Share buybacks (net) | -$278M | -$99M | -$524M | -$301M | -$147M | $0 | -$54,000 | -$270M | -$311M | -$125M |
| Net borrowing | $995M | $559M | $0 | $0 | — | — | — | — | — | — |
| Free cash flow margin | 39.2% | 41.0% | 41.2% | 34.1% | 37.4% | 24.3% | 34.0% | 27.9% | 33.4% | 30.4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for JAZZ.
Open JAZZ in InvestinglyQuestions
What was Jazz Pharmaceuticals's revenue in 2025?
$4.3B in fiscal 2025, from its 10-K filing.
How much free cash flow does Jazz Pharmaceuticals generate?
$1.3B in fiscal 2025 (operating cash flow minus capital spending).
From Jazz Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.